ArticleEye (London, England)2023
Clinical diagnosis and management of Demodex blepharitis: the Demodex Expert Panel on Treatment and Eyelid Health (DEPTH).
Article in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Association between lid margin collarettes and dry eye disease severity in the Dry Eye Assessment and Management (DREAM) study.Eye (London, England) · 2026Trial
- Efficacy of Terpinen-4-ol Combined With Eyelid Deep Cleaning for the Treatment of Demodex Blepharitis: A Randomized, Open-Label Trial.Translational vision science & technology · 2024Trial
- Proportion of patients with Demodex blepharitis in ophthalmology clinics in Europe: the Eos study.Eye (London, England) · 2026Article
- Using Lotilaner Ophthalmic Solution, 0.25% to TreatClinical optometry · 2026Article
- Lotilaner ophthalmic solution 0.25% in the treatment ofSAGE open medical case reports · 2026Article
- Advances in the Medical Management of Pediatric Blepharokeratoconjunctivitis.Advances in therapy · 2026Review
- An Observational, Multicenter, Parallel-Cohort Study Evaluating the Association of Clinical Manifestations and Patient-Reported Outcomes in Patients withClinical optometry · 2026Article
- Blepharitis driven by microbiome dysbiosis andFrontiers in medicine · 2026Review
- Safety and Efficacy of Lotilaner Ophthalmic Solution (0.25%) in Treating Demodex Blepharitis: Pooled Analysis of Two Pivotal Trials.Ophthalmology and therapy · 2025Article
- Demodex and the eye - A review.Indian journal of ophthalmology · 2025Review
- TheClinical ophthalmology (Auckland, N.Z.) · 2025Article
- Intense Pulsed Light Combined with Low Level Blue and Red Light Therapy forClinical ophthalmology (Auckland, N.Z.) · 2025Article
- Reducing ocularFrontiers in allergy · 2025Article
- Article
- Evaluating the role of Demodex infestation and meibomian gland dysfunction in recurrent corneal erosion syndrome.Scientific reports · 2024Article
- Review
- Noninvasive Ocular Surface Workup in Patients with Meibomian Gland Dysfunction Using Microwave-Heated Eye Bag.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Beyond the Surface: Understanding Demodex and Its Link to Blepharitis and Facial Dermatoses.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- Comparison of the Diagnosis and Management of Demodex Blepharitis Between Eye Care Practitioners in India and Australasia - A Survey-Based Comparison.Clinical optometry · 2024Article
- Telemedicine at a University Ophthalmology Practice During the Beginning of the COVID-19 Pandemic.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTwelve ocular surface disease experts convened to achieve consensus about Demodex blepharitis (DB) using a modified Delphi panel process.
methodsOnline surveys were administered using scaled, open-ended, true/false, and multiple-choice questions. Consensus for questions using a 1 to 9 Likert scale was predefined as median scores of 7-9 and 1-3. For other question types, consensus was achieved when 8 of 12 panellists agreed. Questions were randomized, and results of each survey informed the following survey.
resultsTwelve practitioners comprised the Demodex Expert Panel on Treatment and Eyelid Health (DEPTH). Following 3 surveys, experts agreed that DB is chronic (n = 11) and recurrent (n = 12) and is often misdiagnosed. Consensus was achieved regarding inflammation driving symptoms (median = 7; range 7-9), collarettes as the most common sign (n = 10) and pathognomonic for DB (median = 9; range 8-9), and itching as the most common symptom (n = 12). Panellists agreed that DB may be diagnosed based on collarettes, mites, and/or patient symptoms (n = 10) and felt that patients unresponsive to typical therapies should be evaluated for DB (n = 12). Consensus about the most effective currently available OTC treatment was not reached.
conclusionsThe Delphi methodology proved effective in establishing consensus about DB, including signs, symptoms, and diagnosis. Consensus was not reached about the best treatment or how to grade severity. With increased awareness, eyecare practitioners can offer DB patients better clinical outcomes. A follow-up Delphi panel is planned to obtain further consensus surrounding DB treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.